**BIO SKETCH**

# NAME : Christophe BAUDOUIN, MD, PhD

# POSITION TITLE : Professor of Ophthalmology

Date and birth location: May 19, 1961 Cannes (France)

Nationality : French

Affiliations: Quinze-Vingts National Ophthalmology Hospital

 Vision Institute, INSERM UMR968, CNRS5210, university Pierre et Marie Curie

N° Conseil de l’Ordre des Médecins : 75/66479

EDUCATION TRAINING

INSTITUTION AND LOCATION DEGREE YEAR FIELD OF STUDY

University of Nice, France Residency 1984-88 Ophthalmology

University of Nice MS 1987 Immunology

University of Nice MS 1987 Pharmacology

University of Marseilles DEA 1988 Pharmacology

University of Nice Residency 1984-88 Ophthalmology

University of Nice MD 1989 Ophthalmology

University of Paris XII PhD 1992 Ophthalmology/Immunology

University of Versailles Professorship 1995 Ophthalmology

 **Positions and employment**

* Residency in Ophthalmology, University of Nice, 1984-1989.
* Medical Degree Thesis, obtained on October 28, 1988, Nice. Thesis Prize 1989 (Gold medal)
* Qualification in Ophthalmology (Diplôme d'Etudes Spécialisées), obtained on February 2nd 1989.
* Fellowship, School of Medicine/Department of Ophthalmology, University of Nice (1990-1992).
* M2R (Master 2 Research), option Pharmacology, University of Marseilles, 1989.
* University Doctorate Thesis, option Biology (PhD), University Paris XII, 1992. Highest level of distinction.
* Accreditation to supervise Research (HDR), University of Nice, 1993.
* Professor of Ophthalmology, since September 1st, 1995, School of Medicine Paris Ile de France Ouest, University Paris V (1995-2001) then University of Versailles since 2001.
* First Class University Professor since 2004.
* Professor *classe exceptionnelle* since 2011
* Head of the Department of Ophthalmology, Ambroise Paré University Hospital, Boulogne/Seine, since September 1st, 1995.
* Head of Department of Ophthalmology III, Centre Hospitalier National d’Ophtalmologie des Quinze-Vingts, since September 1st, 2000.
* Head of *Equipe d’Accueil* 3123, University Paris 6: “Cell therapy and pharmacology of anterior segment of the eye” (2001-2004)
* Team leader of team #3, INSERM U598, Institut Médical des Cordeliers (2004-2007)
* Team leader of team S12, INSERM UMRS 968, Institut de la Vision since 2008

**Scientific and editorial committees**

* Member of Société Française d'Ophtalmologie (1986-)
* Member of the Association for Research in Vision and Ophthalmology (1988-)
* Member of the American Academy of Ophthalmology (1992-) Award Recognition obtained in 2002
* Member of the International Ocular Inflammation Society (1996-). Member of the International Council (2003-2013)
* Member of the Tear Film and Ocular Society (1998-)
* Member of the international Dry Eye Workshop for new definitions of Dry Eye Syndrome (2004-2007) and of the International Meibomian Gland Dysfunction Workshop (2009-2010)
* Member of the editorial Board of “The Ocular surface”
* Editor-in-Chief of Journal Français d’Ophtalmologie (1998-)
* Vice-president of French Glaucoma Society (1997-)
* Founder and organizer of the *Journées de Réflexions Ophtalmologiques* annual meeting since 2001
* President of the Ophthalmological Society of Paris (2004-2011)
* Elected member for 7 years of the Board of the French Society of Ophthalmology (2009-2016)
* Silver Fellow of ARVO (2011)
* Vice-president of the French Society of Ophthalmology (2011-2012)
* General Secretary of the French Society of Ophthalmology (2012-)
* Member of the American Ophthalmological Society (2012-)
* Member of the Academia Ophthalmologica Internationalis (chair LXXIII) (2013-)
* Member of the European Academy of Ophthalmology (chair XV) (2014-)

**Scientific production**

112 Publications in International Journals from 1987 to 2008

5 patents

Coordination of 5 books and 23 book chapters

90 invitations as speaker in the last three years in international meetings

**Original papers published in International journals (2009-2014)**

**2014**

2014-1. Labbé A, Gabison E, Brignole-Baudouin F, Riancho L, Menashi S, **Baudouin C**. Increased Extracellular Matrix Metalloproteinase Inducer (EMMPRIN) Expression in the Conjunctival Epithelium Exposed to Antiglaucoma Treatments. Curr Eye Res. 2014 May 15:1-8.

2014-2. Bron AJ, Tomlinson A, Foulks GN, Pepose JS, **Baudouin C**, Geerling G, Nichols KK, Lemp MA. Rethinking dry eye disease: a perspective on clinical implications. Ocul Surf. 2014 Apr;12(2 Suppl):S1-31.

2014-3. Liang Q, Pan Z, Sun X, **Baudouin C**, Labbé A. Reis-Bücklers Corneal Dystrophy: A Reappraisal Using in vivo and ex vivo Imaging Techniques. Ophthalmic Res. 2014;51(4):187-95.

2014-4. **Baudouin C**, Aragona P, Van Setten G, Rolando M, Irkeç M, Benítez Del Castillo J, Geerling G, Labetoulle M, Bonini S; ODISSEY European Consensus Group members. Diagnosing the severity of dry eye: a clear and practical algorithm. Br J Ophthalmol. 2014 Mar 13. doi: 10.1136/bjophthalmol-2013-304619. [Epub ahead of print]

2014-5. Virevialle C, Labbé A, Dupont-Monod S, Parent F, **Baudouin C**. Can breast implants be responsible for dry eye? Eye (Lond). 2014 May;28(5):633-4.

2014-6. Voskanyan L, García-Feijoó J, Belda JI, Fea A, Jünemann A, **Baudouin C**; Synergy Study Group. Prospective, unmasked evaluation of the iStent® inject system for open-angle glaucoma: synergy trial. Adv Ther. 2014 Feb;31(2):189-201.

2014-7. Labbé A, **Baudouin C**, Deschênes G, Loirat C, Charbit M, Guest G, Niaudet P. A new gel formulation of topical cysteamine for the treatment of corneal cystine crystals in cystinosis: the Cystadrops OCT-1 study. Mol Genet Metab. 2014 Mar;111(3):314-20.

2014-8. Villani E, **Baudouin C**, Efron N, Hamrah P, Kojima T, Patel SV, Pflugfelder SC, Zhivov A, Dogru M. In vivo confocal microscopy of the ocular surface: from bench to bedside. Curr Eye Res. 2014 Mar;39(3):213-31.

2014-9. Labbé A, Gabison E, Brignole-Baudouin F, Riancho L, Menashi S, **Baudouin C.** Increased Extracellular Matrix Metalloproteinase Inducer (EMMPRIN) Expression in the Conjunctival Epithelium Exposed to Antiglaucoma Treatments. Curr Eye Res. 2014; 15:1-8.

2014-10. Bron AJ, Tomlinson A, Foulks GN, Pepose JS, **Baudouin C,** Geerling G, Nichols KK, Lemp MA. Rethinking dry eye disease: a perspective on clinical implications. Ocul Surf. 2014; 12(2 Suppl):S1-31.

**2013**

2013-1. Denoyer A, Ricaud X, Van Went C, Labbé A, **Baudouin C.** Influence of corneal biomechanical properties on surgically induced astigmatism in cataract surgery. J Cataract Refract Surg. 2013 Jun 8. doi:pii: S0886-3350(13)00400-8.

* 1. Deschamps N, Ricaud X, Rabut G, Labbé A, **Baudouin C**, Denoyer A. The Impact of Dry Eye Disease on Visual Performance While Driving. Am J Ophthalmol. 2013 May 22. doi:pii: S0002-9394(13)00164-5.
	2. Trinh L, Saubaméa B, Auclin F, Denoyer A, Lai-Kuen R, El Hamdaoui M, Labbé A, Despiau Mc, Brignole-Baudouin F, **Baudouin C**. A new technique of endothelial graft: the femtosecond and excimer lasers-assisted endothelial keratoplasty (FELEK). Acta Ophthalmol. 2013 Apr 23. doi: 10.1111/aos.12155.
	3. Desbenoit N, Schmitz-Afonso I, **Baudouin C**, Laprévote O, Touboul D, Brignole-Baudouin F, Brunelle A. Localisation and quantification of benzalkonium chloride in eye tissue by TOF-SIMS imaging and liquid chromatography mass spectrometry. Anal Bioanal Chem. 2013 May;405(12):4039-49.
	4. Labbe A, Liang Q, Zhang Y, Wang Z, Xu L, **Baudouin C,** Sun X. Corneal nerve structure and function in patients with non-Sjogren dry eye: clinical correlations. Invest Ophthalmol Vis Sci. 2013 Jul 5. doi:pii: iovs.13-12370v1. 10.1167/iovs.13-12370.
	5. **Baudouin C**, Denoyer A, Desbenoit N, Hamm G, Grise A. In Vitro and in Vivo Experimental Studies on Trabecular Meshwork Degeneration Induced by Benzalkonium Chloride (An American Ophthalmological Society Thesis). Trans Am Ophthalmol Soc. 2012 Dec;110:40-63.
	6. **Baudouin C**, Aragona P, Messmer EM, Tomlinson A, Calonge M, Boboridis KG, Akova YA, Geerling G, Labetoulle M, Rolando M. Role of hyperosmolarity in the pathogenesis and management of dry eye disease: proceedings of the OCEAN group meeting. Ocul Surf. 2013 Oct;11(4):246-58.
	7. Labbé A, Wang YX, Jie Y, **Baudouin C**, Jonas JB, Xu L. Dry eye disease, dry eye symptoms and depression: the Beijing Eye Study. Br J Ophthalmol. 2013 Nov;97(11):1399-403.
	8. Michée S, Brignole-Baudouin F, Riancho L, Rostene W, **Baudouin C**, Labbé A. Effects of benzalkonium chloride on THP-1 differentiated macrophages in vitro. PLoS One. 2013 Aug 19;8(8):e72459.
	9. Renard JP, Rouland JF, Bron A, Sellem E, Nordmann JP, **Baudouin C**, Denis P, Villain M, Chaine G, Colin J, de Pouvourville G, Pinchinat S, Moore N, Estephan M, Delcourt C. Nutritional, lifestyle and environmental factors in ocular hypertension and primary open-angle glaucoma: an exploratory case-control study. Acta Ophthalmol. 2013 Sep;91(6):505-13.
	10. Tahiri Joutei Hassani R, El Sanharawi M, Adam R, Monin C, Dupont-Monod S, **Baudouin C**. Influence of sutureless 23-gauge sclerotomy architecture on postoperative intraocular pressure decrease: results of a multivariate analysis. Graefes Arch Clin Exp Ophthalmol. 2013 May;251(5):1285-92.
	11. Rouland JF, Traverso CE, Stalmans I, El Fekih L, Delval L, Renault D, **Baudouin C**; for the T2345 Study Group. Efficacy and safety of preservative-free latanoprost eyedrops, compared with BAK-preserved latanoprost in patients with ocular hypertension or glaucoma. Br J Ophthalmol. 2013 Feb;97(2):196-200.
	12. Tahiri Joutei Hassani R, El Sanharawi M, Adam R, Monin C, Dupont-Monod S, **Baudouin C**. Comparison of 23-gauge sutureless sclerotomy architecture and clinical outcomes in macular and non-macular surgery using spectral-domain optical coherence tomography. Acta Ophthalmol. 2013 May;91(3):e203-10.

**2012**

2012-1. Denoyer A, Godefroy D, Célérier I, Frugier J, Degardin J, Harrison JK, Brignole-Baudouin F, Picaud S, Baleux F, Sahel JA, Rostène W, **Baudouin C.** CXCR3 Antagonism of SDF-1(5-67) Restores Trabecular Function and Prevents Retinal Neurodegeneration in a Rat Model of Ocular Hypertension. PLoS One. 2012;7(6):e37873. Epub 2012 Jun 4.

2012-2. Clouzeau C, Godefroy D, Riancho L, Rostène W, **Baudouin C,** Brignole-Baudouin F. Hyperosmolarity potentiates toxic effects of benzalkonium chloride on conjunctival epithelial cells in vitro. Mol Vis. 2012;18:851-63.

2012-3. Liang H, Brignole-Baudouin F, Riancho L, **Baudouin C.** Reduced in vivo Ocular Surface Toxicity with Polyquad-Preserved Travoprost versus Benzalkonium-Preserved Travoprost or Latanoprost Ophthalmic Solutions. Ophthalmic Res. 2012 Apr 3;48(2):89-101.

2012-4. Liang H, **Baudouin C**, Labbe A, Riancho L, Brignole-Baudouin F. Conjunctiva-associated lymphoid tissue (CALT) reactions to antiglaucoma prostaglandins with or without BAK-preservative in rabbit acute toxicity study. PLoS One. 2012;7(3):e33913. Epub 2012 Mar 19.

2012-5. Li J, Roubeix C, Wang Y, Shi S, Liu G, **Baudouin C**, Chen W. Therapeutic efficacy of trehalose eye drops for treatment of murine dry eye induced by an intelligently controlled environmental system. Mol Vis. 2012;18:317-29.

2012-6. Chassignol A, Brasnu E, **Baudouin C,** Riancho L, Warnet JM, Brignole-Baudouin F. In vitro interactions between peripheral blood lymphocytes and the Wong-Kilbourne derivative of Chang conjunctival cells. Invest Ophthalmol Vis Sci. 2012 Mar 21;53(3):1492-8.

2012-7 Denoyer A, Godefroy D, Célérier I, Frugier J, Riancho L, Baudouin F, Rostène W, **Baudouin C**. CX3CL1 expression in the conjunctiva is involved in immune cell trafficking during toxic ocular surface inflammation. Mucosal Immunol. 2012 Nov;5(6):702-11.

2012-8 Denoyer A, Rabut G, **Baudouin C**. Tear Film Aberration Dynamics and Vision-Related Quality of Life in Patients with Dry Eye Disease. Ophthalmology. 2012 Sep;119(9):1811-8.

2012-9 **Baudouin C**, Cochener B, Pisella PJ, Girard B, Pouliquen P, Cooper H, Creuzot-Garcher C. Randomized, phase III study comparing osmoprotective carboxymethylcellulose with sodium hyaluronate in dry eye disease. Eur J Ophthalmol. 2012 Sep-Oct;22(5):751-61.

2012-10 Labbé A, Alalwani H, Brasnu E, Van Went C, Georgescu D, **Baudouin C.** Correlation between in vivo confocal microscopy of subbasal corneal nerves and corneal sensation in ocular surface disease. Invest Ophthalmol Vis Sci, 2012 Jul 24;53(8):4926-31.

2012-11 Labbé A, Terry O, Brasnu E, Van Went C, **Baudouin C**. Tear Film Osmolarity in Patients Treated for Glaucoma or Ocular Hypertension. Cornea 2012 Sep;31(9):994-9.

2012-12 Liang H, **Baudouin C**, Daull P, Guarrigue JS, Brignole-Baudouin F. Ocular Safety of Cationic Emulsion of Cyclosporine in an in vitro Corneal Wound Healing Model and an Acute in vivo Rabbit Model. Mol Vis, 2012;18:2195-204.

2012-13 Brignole-Baudouin F, Desbenoit N, Hamm G, Liang H, Both JP, Brunelle A, Fournier I, Guerineau V, Legouffe R, Stauber J, Touboul D, Wisztorski M, Salzet M, Laprevote O, **Baudouin C**. A new safety concern for glaucoma treatment demonstrated by mass spectrometry imaging of benzalkonium chloride distribution in the eye, an experimental study in rabbits. PLoS One. 2012;7(11):e50180. doi:10.1371/journal.pone.0050180.

2012-14 Pauly A, Roubeix C, Liang H, Brignole-Baudouin F, **Baudouin C.** In vitro and in vivo comparative toxicological study of a new preservative-free latanoprost formulation. Invest Ophthalmol Vis Sci. 2012;53(13):8172-80.

2012-15 Liang H, **Baudouin C**, Daull P, Garrigue JS, Buggage R, Brignole-Baudouin F. In vitro and in vivo evaluation of a preservative-free cationic emulsion of latanoprost in corneal wound healing models. Cornea. 2012;31(11):1319-29.

* 1. **Baudouin C**, Renard JP, Nordmann JP, Denis P, Lachkar Y, Sellem E, Rouland JF, Jeanbat V, Bouée S. Prevalence and risk factors for ocular surface disease among patients treated over the long term for glaucoma or ocular hypertension. Eur J Ophthalmol. 2012 Jun 11:0. doi: 10.5301/ejo.5000181. [Epub ahead of print]
	2. **Baudouin C.** Ocular surface and external filtration surgery: mutual relationships. Dev Ophthalmol. 2012;50:64-78.
	3. Guillemin I, Begley C, Chalmers R, **Baudouin C**, Arnould B. Appraisal of patient-reported outcome instruments available for randomized clinical trials in dry eye: revisiting the standards. Ocul Surf. 2012 Apr;10(2):84-99.

**2011**

2011-1. Brignole-Baudouin F, Riancho L, Liang H, **Baudouin C**. Comparative in vitro toxicology study of travoprost polyquad-preserved, travoprost BAK-preserved, and latanoprost BAK-preserved ophthalmic solutions on human conjunctival epithelial cells. Curr Eye Res. 2011 Nov;36(11):979-88.

2011-2. Huet E, Vallée B, Delbé J, Mourah S, Prulière-Escabasse V, Tremouilleres M, Kadomatsu K, Doan S, **Baudouin C,** Menashi S, Gabison EE. EMMPRIN modulates epithelial barrier function through a MMP-mediated occludin cleavage: implications in dry eye disease. Am J Pathol. 2011 Sep;179(3):1278-86. Epub 2011 Jul 21. Erratum in: Am J Pathol. 2011 Nov;179(5):2674.

2011-3. Pauly A, Brasnu E, Riancho L, Brignole-Baudouin F, **Baudouin C**. Multiple endpoint analysis of BAC-preserved and unpreserved antiallergic eye drops on a 3D-reconstituted corneal epithelial model. Mol Vis. 2011 Mar 16;17:745-55.

2011-4. Liang H, Pauly A, Riancho L, **Baudouin C,** Brignole-Baudouin F. Toxicological evaluation of preservative-containing and preservative-free topical prostaglandin analogues on a three-dimensional-reconstituted corneal epithelium system. Br J Ophthalmol. 2011 Jun;95(6):869-75.

2011-5. Liang H, Brignole-Baudouin F, Pauly A, Riancho L, **Baudouin C**. Polyquad-preserved travoprost/timolol, benzalkonium chloride (BAK)-preserved travoprost/timolol, and latanoprost/timolol in fixed combinations: a rabbit ocular surface study. Adv Ther. 2011 Apr;28(4):311-25.

2011-6. Mehanna C, **Baudouin C**, Brignole-Baudouin F. Spectrofluorometry assays for oxidative stress and apoptosis, with cell viability on the same microplates: a multiparametric analysis and quality control. Toxicol In Vitro. 2011 Aug;25(5):1089-96. Epub 2011 Mar 16.

2011-7. Brignole-Baudouin F, Riancho L, Liang H, Nakib Z, **Baudouin C**. In vitro comparative toxicology of polyquad-preserved and benzalkonium chloride-preserved travoprost/timolol fixed combination and latanoprost/timolol fixed combination. J Ocul Pharmacol Ther. 2011 Jun;27(3):273-80. Epub 2011 Mar 16.

2011-8. Francoz M, Karamoko I, **Baudouin C,** Labbé A. Ocular surface epithelial thickness evaluation with spectral-domain optical coherence tomography. Invest Ophthalmol Vis Sci. 2011 Nov 25;52(12):9116-23.

2011-9. Ricaud X, Rozenbaum JP, Landowski S, **Baudouin C**, Labbé A. Abnormal corneal nerves in a patient with Lyme disease. Eye (Lond). 2011 Nov;25(11):1524-5.

2011-10. Brignole-Baudouin F, **Baudouin C**, Aragona P, Rolando M, Labetoulle M, Pisella PJ, Barabino S, Siou-Mermet R, Creuzot-Garcher C. A multicentre, double-masked, randomized, controlled trial assessing the effect of oral supplementation of omega-3 and omega-6 fatty acids on a conjunctival inflammatory marker in dry eye patients. Acta Ophthalmol. 2011 Nov;89(7):e591-7.

2011-11. Labbé A, Gabison E, Cochereau I, **Baudouin C**. Diagnosis of fungal keratitis by in vivo confocal microscopy: a case report. Eye (Lond). 2011 Jul;25(7):956-8.

2011-12. Lemp MA, Bron AJ, **Baudouin C**, Benítez Del Castillo JM, Geffen D, Tauber J, Foulks GN, Pepose JS, Sullivan BD. Tear osmolarity in the diagnosis and management of dry eye disease. Am J Ophthalmol. 2011 May;151(5):792-798.

2011-13. Pflugfelder SC, **Baudouin C**. Challenges in the clinical measurement of ocular surface disease in glaucoma patients. Clin Ophthalmol. 2011;5:1575-83.

2011-14. Luyckx J, **Baudouin C**. Trehalose: an intriguing disaccharide with potential for medical application in ophthalmology. Clin Ophthalmol. 2011;5:577-81.

2011-15. Geerling G, Tauber J, **Baudouin C**, Goto E, Matsumoto Y, O'Brien T, Rolando M, Tsubota K, Nichols KK. The international workshop on meibomian gland dysfunction: report of the subcommittee on management and treatment of meibomian gland dysfunction. Invest Ophthalmol Vis Sci. 2011;Mar 30;52(4):2050-64.

**2010**

2010-1. Meloni M, Pauly A, Servi BD, Varlet BL, **Baudouin C**. Occludin gene expression as an early in vitro sign for mild eye irritation assessment. Toxicol In Vitro. 2010 Feb;24(1):276-85.

2010-2. Liang H, **Baudouin C**, Dupas B, Brignole-Baudouin F. Live conjunctiva-associated lymphoid tissue analysis in rabbit under inflammatory stimuli using in vivo confocal microscopy. Invest Ophthalmol Vis Sci. 2010 Feb;51(2):1008-15.

2010-3. Gabison EE, Labbé A, Brignole-Baudouin F, Nourry H, Putterman M, Malecaze F, Hoang-Xuan T, **Baudouin C.** Confocal biomicroscopy of corneal intraepithelial neoplasia regression following interferon alpha 2b treatment. Br J Ophthalmol. 2010 Jan;94(1):134-5.

2010-4. Labbé A, Gheck L, Iordanidou V, Mehanna C, Brignole-Baudouin F, **Baudouin C**. An in vivo confocal microscopy and impression cytology evaluation of pterygium activity. Cornea. 2010 Apr;29(4):392-9.

2010-5. Nordmann JP, **Baudouin C**, Renard JP, Denis P, Regnault A, Berdeaux G. Identification of noncompliant glaucoma patients using Bayesian networks and the Eye-Drop Satisfaction Questionnaire. Clin Ophthalmol. 2010 Dec 8;4:1489-96.

2010-6. Nordmann JP, **Baudouin C**, Renard JP, Denis P, Lafuma A, Laurendeau C, Jeanbat V, Berdeaux G. Measurement of treatment compliance using a medical device for glaucoma patients associated with intraocular pressure control: a survey. Clin Ophthalmol. 2010 Jul 30;4:731-9.

2010-7. Gaujoux T, Borsali E, Goldschmidt P, Chaumeil C, **Baudouin C**, Nordmann JP, Sahel JA, Laroche L, Borderie VM. Fungal keratitis in France. Acta Ophthalmol. 2011 Mar;89(2):e215-6.

2010-8. Sellem E, Rouland JF, **Baudouin C**, Bron A, Denis P, Nordmann JP, Renard JP. Predictors of additional intraocular pressure reduction in patients changed to latanoprost/timolol fixed combination. BMC Ophthalmol. 2010 Mar 26;10:10.

2010-9. Denis P, **Baudouin C,** Bron A, Nordmann JP, Renard JP, Rouland JF, Sellem E, Amrane M. First-line latanoprost therapy in ocular hypertension or open-angle glaucoma patients: a 3-month efficacy analysis stratified by initial intraocular pressure. BMC Ophthalmol. 2010 Feb 24;10:4.

2010-10. Iordanidou V, Hamard P, Gendron G, Labbé A, Raphael M, **Baudouin C**. Modifications in corneal biomechanics and intraocular pressure after deep sclerectomy. J Glaucoma. 2010 Apr-May;19(4):252-6.

2010-11. **Baudouin C**, Labbé A, Liang H, Pauly A, Brignole-Baudouin F. Preservatives in eyedrops: the good, the bad and the ugly. Prog Retin Eye Res. 2010 Jul;29(4):312-34.

**2009**

2009-1. Liang H, **Baudouin C**, Faure MO, Lambert G, Brignole-Baudouin F. Comparison of the ocular tolerability of a latanoprost cationic emulsion versus conventional formulations of prostaglandins: an in vivo toxicity assay. Mol Vis. 2009 Aug 25;15:1690-9.

2009-2. Pauly A, Meloni M, Brignole-Baudouin F, Warnet JM, **Baudouin C**. Multiple endpoint analysis of the 3D-reconstituted corneal epithelium after treatment with benzalkonium chloride: early detection of toxic damage. Invest Ophthalmol Vis Sci. 2009 Apr;50(4):1644-52.

2009-3 Nordmann JP, **Baudouin C**, Bron A, Denis P, Rouland JF, Sellem E, Renard JP. Xal-Ease: impact of an ocular hypotensive delivery device on ease of eyedrop administration, patient compliance, and satisfaction. Eur J Ophthalmol. 2009 Nov-Dec;19(6):949-56.

2009-4 Labbé A, Niaudet P, Loirat C, Charbit M, Guest G, **Baudouin C**. In vivo confocal microscopy and anterior segment optical coherence tomography analysis of the cornea in nephropathic cystinosis. Ophthalmology. 2009 May;116(5):870-6.

2009-5 Dupont-Monod S, Labbé A, Fayol N, Chassignol A, Bourges JL, **Baudouin C.** In vivo architectural analysis of clear corneal incisions using anterior segment optical coherence tomography. J Cataract Refract Surg. 2009 Mar;35(3):444-50.

* 1. Labbé A, Dupas B, Offret H, **Baudouin C**, Labetoulle M. Evaluation of keratic precipitates and corneal endothelium in Fuchs' heterochromic cyclitis by in vivo confocal microscopy. Br J Ophthalmol. 2009 May;93(5):673-7.
	2. Labbé A, Khammari C, Dupas B, Gabison E, Brasnu E, Labetoulle M, Baudouin C. Contribution of in vivo confocal microscopy to the diagnosis and management of infectious keratitis. Ocul Surf. 2009 Jan;7(1):41-52.
	3. Gabison EE, Huet E, **Baudouin C**, Menashi S. Direct epithelial-stromal interaction in corneal wound healing: Role of EMMPRIN/CD147 in MMPs induction and beyond. Prog Retin Eye Res. 2009 Jan;28(1):19-33.
	4. **Baudouin C.** Detrimental effect of preservatives in eyedrops: implications for the treatment of glaucoma. Acta Ophthalmol. 2008 Nov;86(7):716-26.